Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Get this delivered to your inbox, and more info about our products and services.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Leerink Partners sees shares of Eli Lilly adding another 19% from here.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
